Compare TGTX & LNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TGTX | LNC |
|---|---|---|
| Founded | 1993 | 1905 |
| Country | United States | United States |
| Employees | N/A | 9423 |
| Industry | Biotechnology: Pharmaceutical Preparations | Life Insurance |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 7.0B |
| IPO Year | 2008 | N/A |
| Metric | TGTX | LNC |
|---|---|---|
| Price | $53.25 | $42.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 16 |
| Target Price | ★ $49.80 | $43.13 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 4.87% |
| EPS Growth | ★ 1746.67 | N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $2,785,000.00 | N/A |
| Revenue This Year | $49.08 | $9.60 |
| Revenue Next Year | $26.69 | $3.73 |
| P/E Ratio | $457.29 | ★ $7.17 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.37 | $32.18 |
| 52 Week High | $59.30 | $46.82 |
| Indicator | TGTX | LNC |
|---|---|---|
| Relative Strength Index (RSI) | 51.91 | 65.51 |
| Support Level | $51.15 | $38.68 |
| Resistance Level | $58.34 | $42.68 |
| Average True Range (ATR) | 2.23 | 0.99 |
| MACD | -0.57 | 0.03 |
| Stochastic Oscillator | 36.41 | 82.87 |
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
Lincoln National Corp operates multiple insurance and retirement businesses. The company's operating segment includes Annuities; Retirement Plan Services; Life Insurance and Group Protection. Its products include fixed and indexed annuities, variable annuities, universal life insurance (UL), variable universal life insurance (VUL), linked-benefit UL and VUL, indexed universal life insurance (IUL), term life insurance, employer-sponsored retirement plans and services, and group life, disability, and dental.